ROCKVILLE, Md., Nov. 14, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its third quarter 2023 financial and operating results.
Third Quarter 2023 Financial Results of OpGen, Inc.
The Company entered into two agreements in October 2023 to improve its cash position consisting of a preferred stock purchase agreement for $1.0 million in gross proceeds with a potential strategic investor and a warrant inducement agreement with an existing institutional investor that, as of November 14, 2023, resulted in gross proceeds of approximately $2.06 million. Nevertheless, the Company has concluded that there is substantial doubt about the Company’s ability to continue as a going concern. The Company continues to actively consider multiple alternatives, including, but not limited to, restructuring or refinancing its debt, seeking additional debt or equity capital, reducing or delaying business activities, selling assets, other strategic financings or transactions and other measures, including obtaining relief under applicable bankruptcy laws. There can be no assurance that the Company will be able to identify or execute on any of these alternatives on acceptable terms or that any of these alternatives will be successful.
In the reporting quarter and year to date, the Company has seen the following key developments:
About OpGen, Inc.
OpGen, Inc. (Rockville, Md., U.S.A.) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, both of which are subject to insolvency proceedings under German and Austrian laws, respectively, since November 6, 2023, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s current product portfolio includes Unyvero and the ARES Technology Platform including ARESdb, NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud.
For more information, please visit www.opgen.com
Forward-Looking Statements
This press release includes statements regarding the third quarter of 2023 and the current business of OpGen. These statements and other statements regarding OpGen’s future plans and goals constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, the risks and uncertainties relating to the insolvency proceedings of Curetis GmbH and Ares Genetics GmbH, our ability to continue to finance our business and operations, the result of any alternatives to mitigate the Company’s cash position, including restructuring or refinancing of our debt, seeking additional debt or equity capital, reducing or delaying our business activities, selling assets, other strategic transactions or other measures, including obtaining relief under U.S. bankruptcy laws, and the terms, value and timing of any transaction resulting from such alternatives, our ability to satisfy debt obligations under our loan with the European Investment Bank, and our liquidity and working capital requirements. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
OpGen:
Oliver Schacht
President and CEO
This email address is being protected from spambots. You need JavaScript enabled to view it.
OpGen Investor & Press Contact:
Alyssa Factor
Edison Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
| OpGen, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (unaudited) | ||||||||
| September 30, 2023 | December 31, 2022 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 292,642 | $ | 7,440,030 | ||||
| Accounts receivable, net | 422,725 | 514,372 | ||||||
| Inventory, net | 1,198,259 | 1,345,137 | ||||||
| Prepaid expenses and other current assets | 1,541,074 | 1,355,949 | ||||||
| Total current assets | 3,454,700 | 10,655,488 | ||||||
| Property and equipment, net | 3,820,829 | 3,457,531 | ||||||
| Finance lease right-of-use assets, net | 986 | 3,500 | ||||||
| Operating lease right-of-use assets | 1,915,049 | 1,459,413 | ||||||
| Intangible assets, net | 6,842,406 | 7,440,974 | ||||||
| Strategic inventory | 1,608,890 | 2,300,614 | ||||||
| Other noncurrent assets | 492,022 | 495,629 | ||||||
| Total assets | $ | 18,134,882 | $ | 25,813,149 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities | ||||||||
| Current maturities of long-term debt | $ | 9,199,764 | $ | 7,023,901 | ||||
| Accounts payable | 904,559 | 420,821 | ||||||
| Accrued compensation and benefits | 381,807 | 1,097,654 | ||||||
| Accrued liabilities | 1,268,723 | 1,526,204 | ||||||
| Deferred revenue | 194,687 | 142,061 | ||||||
| Short-term finance lease liabilities | 1,121 | 3,364 | ||||||
| Short-term operating lease liabilities | 521,424 | 377,626 | ||||||
| Total current liabilities | 12,472,085 | 10,591,631 | ||||||
| Long-term debt, net | — | 4,850,686 | ||||||
| Derivative liabilities | 34,364 | 99,498 | ||||||
| Long-term finance lease liabilities | — | 280 | ||||||
| Long-term operating lease liabilities | 2,830,282 | 2,566,138 | ||||||
| Other long-term liabilities | 121,428 | 129,368 | ||||||
| Total liabilities | 15,458,159 | 18,237,601 | ||||||
| Stockholders’ equity | ||||||||
| Preferred stock, $0.01 par value; 10,000,000 shares authorized; none issued and outstanding at September 30, 2023 and December 31, 2022 | — | — | ||||||
| Common stock, $0.01 par value; 100,000,000 shares authorized; 10,013,524 and 2,899,911 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | 100,135 | 28,999 | ||||||
| Additional paid-in capital | 291,705,905 | 281,167,161 | ||||||
| Accumulated deficit | (288,451,655 | ) | (272,824,772 | ) | ||||
| Accumulated other comprehensive loss | (677,662 | ) | (795,840 | ) | ||||
| Total stockholders’ equity | 2,676,723 | 7,575,548 | ||||||
| Total liabilities and stockholders’ equity | $ | 18,134,882 | $ | 25,813,149 | ||||
| OpGen, Inc. and Subsidiaries Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) | ||||||||||||||||||
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||||
| Revenue | ||||||||||||||||||
| Product sales | $ | 558,965 | $ | 359,112 | $ | 1,409,534 | $ | 1,614,435 | ||||||||||
| Laboratory services | 47,135 | 31,016 | 112,810 | 94,515 | ||||||||||||||
| Collaboration revenue | 92,922 | 58,585 | 826,257 | 176,713 | ||||||||||||||
| Total revenue | 699,022 | 448,713 | 2,348,601 | 1,885,663 | ||||||||||||||
| Operating expenses | ||||||||||||||||||
| Cost of products sold | 618,796 | 1,886,191 | 1,925,566 | 2,824,577 | ||||||||||||||
| Cost of services | 73,174 | 17,239 | 405,582 | 63,450 | ||||||||||||||
| Research and development | 1,201,865 | 2,031,113 | 4,403,488 | 6,621,310 | ||||||||||||||
| General and administrative | 2,034,628 | 2,020,452 | 6,883,588 | 6,779,773 | ||||||||||||||
| Sales and marketing | 336,184 | 1,031,496 | 2,522,471 | 3,252,277 | ||||||||||||||
| Goodwill impairment charge | — | 6,975,520 | — | 6,975,520 | ||||||||||||||
| Total operating expenses | 4,264,647 | 13,962,011 | 16,140,695 | 26,516,907 | ||||||||||||||
| Operating loss | (3,565,625 | ) | (13,513,298 | ) | (13,792,094 | ) | (24,631,244 | ) | ||||||||||
| Other (expense) income | ||||||||||||||||||
| Interest and other income | 24,977 | 11,174 | 86,301 | 28,147 | ||||||||||||||
| Interest expense | (396,768 | ) | (569,306 | ) | (1,698,564 | ) | (2,618,799 | ) | ||||||||||
| Foreign currency transaction (losses) gains | (135,930 | ) | (51,547 | ) | (288,326 | ) | 419,160 | |||||||||||
| Change in fair value of derivative financial instruments | 10,389 | 18,995 | 65,800 | 54,623 | ||||||||||||||
| Total other expense | (497,332 | ) | (590,684 | ) | (1,834,789 | ) | (2,116,869 | ) | ||||||||||
| Loss before income taxes | (4,062,957 | ) | (14,103,982 | ) | (15,626,883 | ) | (26,748,113 | ) | ||||||||||
| Provision for income taxes | — | — | — | — | ||||||||||||||
| Net loss | $ | (4,062,957 | ) | $ | (14,103,982 | ) | $ | (15,626,883 | ) | $ | (26,748,113 | ) | ||||||
| Net loss available to common stockholders | $ | (4,062,957 | ) | $ | (14,103,982 | ) | $ | (15,626,883 | ) | $ | (26,748,113 | ) | ||||||
| Net loss per common share – basic and diluted | $ | (0.46 | ) | $ | (5.92 | ) | $ | (2.38 | ) | $ | (11.40 | ) | ||||||
| Weighted average shares outstanding – basic and diluted | 8,778,152 | 2,382,848 | 6,565,853 | 2,345,794 | ||||||||||||||
| Net loss | $ | (4,062,957 | ) | $ | (14,103,982 | ) | $ | (15,626,883 | ) | $ | (26,748,113 | ) | ||||||
| Other comprehensive income (loss) – foreign currency translation | 78,815 | (536,758 | ) | 118,178 | (2,247,749 | ) | ||||||||||||
| Comprehensive loss | $ | (3,984,142 | ) | $ | (14,640,740 | ) | $ | (15,508,705 | ) | $ | (28,995,862 | ) | ||||||
| Last Trade: | US$0.60 |
| Daily Change: | -1.30 -68.53 |
| Daily Volume: | 3,912 |
| Market Cap: | US$6.020M |
October 12, 2023 July 19, 2023 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
